Akero Therapeutics Inc (AKRO) - Total Assets
Based on the latest financial reports, Akero Therapeutics Inc (AKRO) holds total assets worth $1.01 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Akero Therapeutics Inc - Total Assets Trend (2017–2024)
This chart illustrates how Akero Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see Akero Therapeutics Inc (AKRO) market capitalisation for the company's overall valuation and market capitalisation.
Akero Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Akero Therapeutics Inc's total assets of $1.01 Billion consist of 93.3% current assets and 6.7% non-current assets. Review Akero Therapeutics Inc debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 41.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Akero Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Akero Therapeutics Inc (AKRO) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Akero Therapeutics Inc's current assets represent 93.3% of total assets in 2024, a decrease from 97.0% in 2017.
- Cash Position: Cash and equivalents constituted 41.2% of total assets in 2024, down from 90.9% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Akero Therapeutics Inc Competitors by Total Assets
Key competitors of Akero Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Akero Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.83 | 17.25 | 20.70 |
| Quick Ratio | 15.83 | 17.25 | 20.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $706.88 Million | $703.60 Million | $258.23 Million |
Akero Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Akero Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.70 |
| Latest Market Cap to Assets Ratio | 5.45 |
| Asset Growth Rate (YoY) | 42.3% |
| Total Assets | $825.89 Million |
| Market Capitalization | $4.50 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Akero Therapeutics Inc's assets at a significant premium (5.45x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Akero Therapeutics Inc's assets grew by 42.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Akero Therapeutics Inc (2017–2024)
The table below shows the annual total assets of Akero Therapeutics Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $825.89 Million | +42.33% |
| 2023-12-31 | $580.27 Million | +62.74% |
| 2022-12-31 | $356.57 Million | +82.34% |
| 2021-12-31 | $195.55 Million | -28.46% |
| 2020-12-31 | $273.34 Million | +97.90% |
| 2019-12-31 | $138.12 Million | +79.02% |
| 2018-12-31 | $77.15 Million | +11625.08% |
| 2017-12-31 | $658.00K | -- |
About Akero Therapeutics Inc
Akero Therapeutics, Inc. engages in developing transformational treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic… Read more